Analyst Ratings for CTI BioPharma
CTI BioPharma CTIC observed the following analyst notes during the last quarter:
These 4 analysts have an average price target of $11.0 from CTI BioPharma's current price of $4.855, implying upside.
Below is a summary of how these 4 analysts rated CTI BioPharma over the past 3 months. The higher the number of bullish ratings, the more analysts are positive on the security and the higher the number of bearish ratings, the more analysts are negative on the security
This current average is up 57.14% from the previous average price target of $7.00.
Keep up to date with CTI BioPharma analyst ratings.
If you want to follow small cap stock news and performance, you can start by following it here.
Ratings come from analysts or specialists in banking and financial systems who publish reports for specific stocks or defined sectors (usually once a quarter for each stock). Analysts typically draw their information from company conference calls and meetings, financial statements, and conversations with important insiders to make their decisions.
Some analysts will also offer forecasts for metrics such as growth estimates, earnings and revenue to provide additional insights into stocks. Investors using analyst ratings should note that such expert advice is human-sourced and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
CTI BioPharma CTIC observed the following analyst notes during the last quarter:
These 4 analysts have an average price target of $11.0 from CTI BioPharma's current price of $4.855, implying upside.
Below is a summary of how these 4 analysts rated CTI BioPharma over the past 3 months. The higher the number of bullish ratings, the more analysts are positive on the security and the higher the number of bearish ratings, the more analysts are negative on the security
This current average is up 57.14% from the previous average price target of $7.00.
Keep up to date with CTI BioPharma analyst ratings.
If you want to follow small cap stock news and performance, you can start by following it here.
Ratings come from analysts or specialists in banking and financial systems who publish reports for specific stocks or defined sectors (usually once a quarter for each stock). Analysts typically draw their information from company conference calls and meetings, financial statements, and conversations with important insiders to make their decisions.
Some analysts will also offer forecasts for metrics such as growth estimates, earnings and revenue to provide additional insights into stocks. Investors using analyst ratings should note that such expert advice is human-sourced and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
What's Your Reaction?
